

Common Drug Codes for India (Flat Files Package)

Release Date: June 20, 2025

Introduction

Drugs (medicinal products) are one of the key data points captured and referred for continuity of care of an individual. In order for the drug information to be identified, stored, referred, and exchanged between different clinical, reporting, stock, supply chain, the dispensation systems, it is important to have common drug codes across those systems.

Lack of common drug codes across different systems and healthcare setups invariably introduced local maps, formats, and naming conventions leading to input errors, missing information, incorrect identification, and other problems that surface due to the lack of unique identities and diverging naming methodologies. This makes the exchange of health data a difficult and error-prone activity.

For a country rapidly digitizing its information systems and especially adopting digital systems in healthcare information management, this key piece of information must be codified and made available for use across all systems. A different system should be able to use the same codes with slightly different additional information to meet its purposes.

National Resource Centre for EHR Standards (NRCeS), a program of the Ministry of Health and Family Welfare (MoHFW), the Government of India is providing these Common Drug Codes for India for use across healthcare records, supply and pharmacy systems.

Release Summary

Common Drug Codes for India (Flat Files Package) has been introduced to support standardized coding and sharing of drug codes without the need of integrating the complete Terminology.

This release of Common Drug Codes for India (Flat Files Package) includes generic (clinical drug), supplier, and branded medicine codes and human-readable descriptions which covers all medicines, except devices, surgical implants, and combi packs, from:

- National List of Essential Medicines (NLEM) 2015 & 2022
- Pradhan Mantri Jan-Aushadhi Yojana
- Affordable Medicines and Reliable Implants for Treatment (AMRIT) programme
- Medicines referred in Telemedicine Practice Guidelines
- HIV Drug list referred by the National AIDS Control Organization
- COVID-19 drug list referred in CLINICAL MANAGEMENT PROTOCOL: COVID-19 by MoHFW
- COVID-19 Vaccine Product (Covishield, Covaxin, and Sputnik V)

The package provides a **Tab Separated Values in text files** and covers codes for Substances, Generic Medicines, and Branded Medicines. The package contains for following files:

File Name	Description	Count
Substance Master	Contains a list of substances used as active ingredients in medicinal products	27724
Generic Master	Provides a list of generic medicines and reference to substance and the drug form	9504
Brand Master	Provides a list of branded medicines and reference to generic medicine	83478
Product Name Master	Contains a list of authorized marketed names of the medicine as labeled by the manufacturer (supplier)	63495
Supplier Master	Contains the list of Suppliers (may be licensed holder or distributor)	7567
Drug Form Master	Contains the list of physical forms of a medicine describing Mechanism of action, route, and package container	418
Route Of Administration Master	Contains the list of routes by which the medicine is taken into the body	160

Common Drug Codes for India (Flat Files Package) is available for use under the terms provided in the *License.txt* file included in the Package.

The CDCI package is developed by following a rigorous process of authoring and review of the drug and related concepts. It is determined that the package is suitable for use in clinical systems. However, implementers and users are expected to check its suitability for their own environment. In evidence of any material error, change or correction you are requested to immediately report it at nrc-help@cdac.in.

Acknowledgement & Contributions

This package includes a drug information corpus contributed by the *All India Institute of Medical Sciences (AIIMS)*, New Delhi; *1MG Technologies Private Limited*, Gurgaon, Haryana; *Center for Development of Advanced Computing (C-DAC)*- Noida Centre, RailTel Corporation, and Pfizer Ltd., India.

Computer Facility, AIIMS, New Delhi facilitated the content review and validation for correctness and completeness.